Scipher Medicine, recently under new leadership, is transitioning beyond its commercial molecular assay for rheumatoid arthritis to broader personalized medicine applications across non-oncology immune-mediated diseases. Leveraging the world’s largest non-oncology clinical transcriptomic dataset, the company has pursued multiple data-sharing partnerships with pharmaceutical companies and informatics firms to foster biomarker discovery, drug development, and real-world evidence generation. A recent collaboration with Savant Bio integrates advanced data extraction and AI tools to correlate transcriptomic data with clinical parameters, unlocking new avenues for academic research and clinical trial design. Scipher aims to emulate precision oncology’s success with comprehensive omics platforms by enabling immunology-focused biomarker-driven therapeutic strategies.